Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you discover you are pregnant while taking tirzepatide, stop the medicine and speak to your GP or midwife as soon as possible. Tirzepatide is not licensed for use in pregnancy; current UK guidance recommends stopping treatment before trying to conceive, and the medicine should not be used during pregnancy or while breastfeeding. This page covers what is known, what remains uncertain, and the practical steps to take right now. For questions about ongoing weight management or private treatment options, a prescriber can discuss what comes next once your maternity care is under way — you can start a free consultation with our clinical team when the time is right.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first action is straightforward. Stop your tirzepatide pen immediately. Do not take the next scheduled dose. Then contact your GP surgery, an NHS 111 adviser or your midwife (whichever you can reach fastest) and tell them you were taking tirzepatide when you found out you were pregnant.
This matters because tirzepatide's half-life means the medicine does not leave your system the moment you put the pen down. It remains detectable for several weeks, so your maternity team needs a full picture from the outset. They are not going to panic; they need the information to make the right monitoring decisions.
If you were prescribed tirzepatide through a private service, let that prescriber know as well. At nume, our aftercare team is available seven days a week, you can reach us via the contact page and a prescriber will be informed promptly so your record is updated and no repeat supply is issued.
The NHS medicines page for tirzepatide confirms that the medicine should not be taken during pregnancy and that women who could become pregnant should use effective contraception while on treatment.
Tirzepatide has not been studied in human pregnancies. That is not unusual for medicines in this class; clinical trials routinely exclude pregnant participants for ethical reasons. What exists is animal reproductive toxicology data from the regulatory review process, which showed adverse effects at doses higher than those used clinically. Those findings informed the SmPC's recommendation against use in pregnancy, but they cannot be directly translated into precise risk estimates for humans.
In plain terms: the guidance to stop is precautionary, not a statement that something has definitely gone wrong. If you have already been through this and want to understand what others in the same situation experienced, our page on what happened when people got pregnant on tirzepatide brings together those accounts honestly. Many people will have been on the starter 2.5 mg dose (present primarily to help your system adjust rather than as the main therapeutic level) for only a few weeks before finding out. Your obstetric team will factor all of this in.
For a fuller discussion of how tirzepatide works and what the clinical trials showed in adults without pregnancy, the Mounjaro overview page covers the background clearly. Questions specific to what the pregnancy means going forward belong with your midwife or obstetrician.
Most pregnancies in this context come as a surprise, and often the contraception picture is complicated. Women taking tirzepatide who rely on the oral contraceptive pill should know that tirzepatide can reduce absorption of oral hormonal contraceptives during the first four weeks of treatment and for four weeks after each dose increase. NHS guidance recommends adding a barrier method during those windows. The NHS England guidance on weight-management injections sets this out clearly and is worth reading if you want the detail.
If you are planning to try for a baby in future, the advice is to stop tirzepatide before attempting to conceive and allow time for the medicine to clear. Our page on whether you can get pregnant on tirzepatide explains the fertility and conception considerations in more detail, including what to discuss with your GP or prescriber about washout timing, as individual factors matter.
Breastfeeding is also not recommended while on tirzepatide; it is not known whether the medicine passes into breast milk. Raise this with your midwife and postnatal team well before birth so there is a plan in place. If you want to read about the broader picture of pregnancy and tirzepatide together, including what monitoring is typically recommended, that page covers the topic in depth. The getting pregnant on tirzepatide page covers the pre-conception planning side in more depth if that is relevant to you at a later stage.
Stopping tirzepatide is the right call now, but managing weight remains a legitimate health concern and one that does not disappear during or after pregnancy. Your maternity team will monitor your weight as part of standard obstetric care. For anyone who wants to understand the clinical picture while the pregnancy continues, our page on tirzepatide when pregnant sets out what is currently known and what your obstetric team is likely to consider. After the pregnancy, if you want to return to a clinician-supervised weight-loss programme, that conversation can happen with a prescriber at the right time.
Private treatment through a GPhC-registered online pharmacy like nume requires a fresh clinical assessment before any prescription is issued, no previous treatment automatically carries over. When you are ready, our weight-loss treatment options page explains what is available and who it suits. Every consultation is reviewed personally by a GPhC-registered Independent Prescriber, not automated software. Orders approved before midday arrive via DPD the next working day in plain, unbranded packaging, with a tracking link sent to your phone.
If you have questions about the clinical team and how prescribing decisions are made, our lead prescriber's profile gives a clear picture of the oversight behind every decision. You can also browse general FAQs for common questions about the service.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.